Skip to main content

Table 2 Combination regimens used to treat ensuing septic episodes in our patient

From: Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report

Date of hospitalization in Infectious Diseases Unit Microbiological data Combination therapy Doses Timing of therapy
10 April 2016
(first septic episode)
KPC-producing Klebsiella pneumoniae
isolates on BCs
Tigecycline
Meropenem
Colistin
LD 100 mg + 50 mg/12 hours
LD 2gr + 2gr/8 hours
LD 9 MU + 4.5 MU/8 hours
18 days
June 2016
Re-hospitalization for the second septic episode
KPC-producing Klebsiella pneumoniae on BCs Tigecycline
Meropenem
Colistin
LD 100 mg + 50 mg/12 hours
LD 2gr + 2gr/8 hours
LD 9 MU + 4.5 MU/12 hours
12 days before surgical management for fixators’ removal
Continuing hospitalization after surgical treatment   Same combination therapy as above   21 days
December. 2016
Third septic recurrence with hospitalization
KPC-producing Klebsiella pneumoniae and Enterobacter aerogenes isolates on BC Tigecycline
Meropenem
Colistin
Gentamycin
LD 100 mg + 50 mg/12 hours
LD 2gr + 2gr/8 hours
LD 9 MU +  4.5 MU/8 hours
14 days
Septic shock/MOF after discontinuation of therapy
(January 2017)
KPC-producing Klebsiella pneumoniae with a progression of a resistance phenotype isolates on BC Avibactam/ceftazidime
(compassionate use)
Tigecycline
Meropenem
Gentamycin
2gr/8 hours
LD 100 mg + 50 mg/12 hours
LD 2gr + 2gr/8 hours
LD 7 mg/kg per day (480 mg) + 5 mg/kg per day (350 mg/24 hours)
16 days
  1. BCs blood cultures, KPC Klebsiella pneumoniae carbapenemase, LD loading dose, MOF multiple organ failure, MU monitor unit